FDA Section 361 vs 351 Biologic Procurement Checklist

An FDA Section 361 vs 351 compliance checklist for biologic procurement is an operational audit protocol that practices use to verify FDA Form 3356 registrations, donor eligibility documentation, and processing claims before purchasing human tissue allografts. Because purchasing non-exempt Section 351 biological drugs masquerading as Section 361 tissues exposes clinics to federal warning letters and civil liability, purchasing teams must independently validate manufacturing and marketing claims. This step-by-step checklist outlines the mandatory documentation, validation criteria, and supplier red flags required to vet biologics vendors securely.

Understanding the Regulatory Divide in Regenerative Medicine

For medical practice managers overseeing procurement, the distinction between Section 361 and Section 351 of the Public Health Service (PHS) Act is the foundation of risk management in regenerative medicine. When adding or expanding service lines involving biologics—such as amniotic allografts, Wharton’s Jelly, cord blood, or MSC exosomes—administrators cannot rely solely on a sales representative's verbal assurances.

The FDA regulates HCT/Ps under a tiered, risk-based framework established in 21 CFR Part 1271. Products that meet specific, narrow criteria are regulated under Section 361. The primary goal of Section 361 regulation is preventing the introduction, transmission, and spread of communicable diseases. These products do not require premarket approval (such as a Biologics License Application, or BLA) or an Investigational New Drug (IND) application to be marketed.

Conversely, if an HCT/P fails to meet even one of the Section 361 criteria, it defaults to regulation under Section 351, in addition to the Food, Drug, and Cosmetic Act. Section 351 products are legally classified as drugs, devices, and/or biological products. To be legally marketed and administered for clinical revenue, a Section 351 product requires an approved BLA. If it is in the research phase, it must be administered under an active IND application with strict clinical trial protocols, typically prohibiting standard commercial billing.

Understanding where a vendor’s product falls—and how the FDA interprets the boundary between the two sections—is critical for compliant practice operations.

The Four Pillars of 21 CFR 1271.10(a)

To be regulated solely under Section 361, an HCT/P must satisfy all four conditions set forth in 21 CFR 1271.10(a). If a vendor claims 361 status for their allograft or tissue product, the practice manager and medical director should evaluate the product against these four pillars:

1. Minimal Manipulation

For structural tissue (such as bone, skin, amniotic membrane, or umbilical cord tissue), minimal manipulation means that the processing does not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. For cells or nonstructural tissues (such as cord blood), it means processing does not alter the relevant biological characteristics of the cells or tissues. Grinding, lyophilizing, or decellularizing a structural tissue beyond certain thresholds often crosses the line into "more than minimal manipulation," pushing the product into the 351 category.

2. Homologous Use Only

Homologous use means the repair, reconstruction, replacement, or supplementation of a recipient's cells or tissues with an HCT/P that performs the same basic function or functions in the recipient as in the donor. Importantly, the FDA evaluates homologous use based on the labeling, advertising, and objective intent of the manufacturer. For example, amniotic membrane serves as a physical barrier and covering in the donor. Marketing it strictly as a protective wound covering aligns with homologous use; marketing it to regenerate cartilage in an osteoarthritic joint generally does not.

3. No Combination with Other Articles

The HCT/P cannot be combined with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent—provided that the addition of these allowable agents does not raise new clinical safety concerns.

4. Systemic Effect and Metabolic Activity

The HCT/P must either:

• Not have a systemic effect and not be dependent upon the metabolic activity of living cells for its primary function; OR
• If it does have a systemic effect or is dependent on the metabolic activity of living cells, it must be for autologous use (same patient), allogeneic use in a first-degree or second-degree blood relative, or reproductive use.

FDA Section 361 vs 351 Compliance Checklist for Biologic Procurement

When evaluating distributors and manufacturers, practice administrators should implement a standardized vetting protocol. Use the following compliance checklist to audit potential vendors before signing procurement agreements or placing inventory orders.

Phase 1: Entity Registration and Accreditation Verification

• Verify FDA Establishment Registration: Obtain the manufacturer’s FEI (FDA Establishment Identifier) number and verify their active status in the FDA’s Human Cell and Tissue Establishment Registration (HCTERS) database. Note the exact activities they are registered for (e.g., recovery, screening, testing, processing, storage, labeling, packaging, distribution).
• Understand Registration Limitations: Confirm with your team that an FDA Establishment Registration is not an FDA approval of the product. Any vendor marketing their product as "FDA Approved" solely on the basis of a 361 tissue bank registration is misrepresenting their regulatory status.
• Request AATB Accreditation: While not a federal mandate, accreditation by the American Association of Tissue Banks (AATB) indicates that the processing facility adheres to rigorous industry standards for tissue recovery, processing, and quality assurance.
• Verify Distributor Licensing: If purchasing through a third-party distributor rather than directly from the tissue bank, verify the distributor’s state-level medical device or tissue distribution licenses and their cold-chain logistics capabilities.

Phase 2: Product Classification and Regulatory Pathway

• Review the Regulatory Justification Letter: Request the manufacturer’s formal position paper or regulatory justification explaining how the specific product meets all four criteria of 21 CFR 1271.10(a), if marketed as a 361 product.
• Check for TRG Letters: Ask if the manufacturer has submitted the product to the FDA’s Tissue Reference Group (TRG) for a jurisdictional recommendation, and ask to review the redacted response. While non-binding, a TRG letter provides insight into how the agency views the product's processing and intended use.
• Verify 351 Credentials (If Applicable): If the vendor states the product is regulated under Section 351, demand the BLA approval number. If the vendor claims the product is covered under an IND, recognize that an IND is permission to conduct a clinical study—not a license to sell a product commercially to medical practices for routine cash-pay treatments.
• Audit Enforcement History: Search the FDA’s compliance and enforcement databases for the manufacturer’s name and the specific product names. Look for Untitled Letters, Warning Letters, or recalls issued over the past several years.

Phase 3: Labeling, Marketing, and Intended Use Audit

• Inspect the Package Insert: Review the official product insert. For a 361 structural tissue, the labeling should describe the tissue's structural properties and homologous function, avoiding therapeutic claims about curing diseases or systemic cellular regeneration.
• Evaluate Vendor Marketing Collateral: Review the brochures, patient-facing materials, and website copy provided by the vendor. Because the FDA determines "intended use" largely from promotional claims, a vendor making unsubstantiated clinical claims on their website can inadvertently turn an otherwise compliant tissue into an unapproved 351 drug in the eyes of regulators.
• Assess Point-of-Care Autologous Systems: If procuring centrifuge kits and supplies for Platelet-Rich Plasma (PRP), verify that the system holds an FDA 510(k) clearance for the specific preparation of autologous PRP.

Phase 4: Chain of Custody and Quality Assurance

• Review Donor Eligibility Protocols: Request documentation detailing how the tissue bank complies with 21 CFR Part 1271 Subpart C regarding donor screening and infectious disease testing (e.g., HIV, Hepatitis B and C, Syphilis, West Nile Virus, Zika).
• Obtain Sample Certificates of Analysis (CoA): Review a sample CoA or Certificate of Compliance that accompanies each lot. Confirm what sterility testing (such as USP <71>) and endotoxin testing are performed prior to lot release.
• Establish Cold-Chain and Adverse Event SOPs: Confirm how the vendor validates shipping temperatures (e.g., dry ice weight, temperature loggers) and verify their standard operating procedure for tracking grafts from donor to recipient, as well as reporting potential adverse reactions.

Clinical Considerations for Physicians and Medical Directors

While practice managers handle vendor vetting, contracts, and inventory logistics, the regulatory classification of an HCT/P directly impacts the treating physician’s clinical workflow, charting, and malpractice exposure. Physicians across various clinical specialties—from orthopedics and pain management to aesthetics—must align their clinical documentation and patient communications with the regulatory reality of the products they utilize.

First, physicians must understand the boundaries of the "practice of medicine" exemption. While the FDA does not regulate how a licensed physician practices medicine, the agency strictly regulates the manufacturing and interstate commerce of unapproved drugs and biologics. Administering an unapproved 351 product that was illegally marketed by a vendor exposes the clinician to regulatory scrutiny and potential liability, as medical malpractice carriers frequently exclude coverage for the administration of unapproved drugs outside of a sanctioned clinical trial.

Second, clinical charting and informed consent must be precise. When utilizing structural allografts or autologous preparations like PRP alongside regenerative medical devices (such as extracorporeal shockwave therapy or high-power laser therapy), the medical record should accurately reflect the homologous or cleared function of each modality. Physicians should ensure their internal marketing team and front-desk staff do not use consumer-facing language that promises guaranteed tissue regeneration or disease modification.

What This Means for Your Practice

Building a sustainable, compliant regenerative service line requires disciplined procurement. Before introducing a new biologic product or switching suppliers, your administrative and clinical leadership should take the following concrete actions:

1. Audit Current Inventory: Run your existing biologic inventory and vendor files through the four-phase checklist above. Ensure you have active FDA registration printouts, AATB certificates, and sample package inserts on file for every tissue product in your clinic.
2. Align Marketing with Labeling: Conduct an internal audit of your practice’s website, social media, and patient consent forms. Remove hyperbolic language or therapeutic claims that conflict with the homologous use criteria of 21 CFR 1271.10(a).
3. Standardize Receiving Logs: Update your clinical receiving protocols to ensure staff log lot numbers, expiration dates, and shipping temperature integrity upon arrival, maintaining a strict chain of custody from the distributor to the patient chart.
4. Partner with Vetted Distributors: Consolidate your purchasing with established distributors who prioritize regulatory transparency and maintain proper state licensing.

Navigating the complexities of HCT/P regulations does not have to slow down your clinic's operational growth. You can learn more about how Dallas Regenerative Solutions supports licensed providers with compliant procurement, or reach out via our contact page to schedule a consultation regarding your practice's biologic and device supply chain.